Systemic Lupus Erythematosus in Gullah Health
Launched by MEDICAL UNIVERSITY OF SOUTH CAROLINA · Sep 18, 2008
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
**Summary of the Clinical Trial: Systemic Lupus Erythematosus in Gullah Health**
This clinical trial is studying systemic lupus erythematosus (SLE), an autoimmune disease where the body mistakenly attacks its own tissues, affecting various organs and causing a range of symptoms. The focus is on the Gullah community of African Americans from the Sea Islands of South Carolina and Georgia, who are at a higher risk for SLE. Researchers believe that certain genetic factors, along with environmental influences, may play a role in the development of this disease. The Gullah population is unique because they share a similar genetic background, which helps scientists better understand how these factors contribute to SLE.
To participate in this study, you need to be at least 2 years old, identify as Gullah from the Sea Islands, and either have a diagnosis of SLE (with at least 4 out of 11 specific symptoms) or be a relative of someone with SLE. Healthy individuals from the Gullah community can also take part as control subjects. Participants will be asked to provide informed consent and will be involved in activities that help researchers gather important information about SLE. This study aims to improve understanding of the disease and ultimately lead to better treatments for those affected. If you’re interested or know someone who might be eligible, this could be a valuable opportunity to contribute to important research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 2 years and above;
- • Self-identified as African-American "Gullah" from the Sea Island region of South Carolina;
- • Have had at least 4 of the 11 diagnostic criteria for SLE as designated by the American College of Rheumatology (ACR), be a relative of a known SLE patient, or be an unrelated healthy Gullah control;
- • Ability to speak and understand English;
- • Ability and willingness to give informed consent
- Exclusion Criteria:
- • Race defined by participant as other than Black or African-American;
- • Being a prisoner, mentally ill patient, or institutionalized individual;
- • Unwilling or unable to give informed consent
About Medical University Of South Carolina
The Medical University of South Carolina (MUSC) is a leading academic health center dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong emphasis on translational medicine, MUSC leverages its extensive resources and expertise to facilitate groundbreaking studies across various medical disciplines. The institution is committed to fostering collaboration among researchers, healthcare professionals, and patients, ensuring that cutting-edge discoveries translate into effective treatments. As a pioneer in health education and research, MUSC plays a vital role in shaping the future of medicine and enhancing health outcomes in the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charleston, South Carolina, United States
Patients applied
Trial Officials
Diane L. Kamen, MD, MSCR
Principal Investigator
Medical University of South Carolina
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials